What is the approximate price of Milizumab in the domestic market?
Milikizumab(Mirikizumab) is a new biologic agent mainly used to treat moderately to severely active ulcerative colitis(UC). It reduces inflammatory responses by inhibiting specific immune pathways, thereby effectively relieving patients' symptoms and improving quality of life. Clinical studies of militizumab have shown good efficacy and tolerability, making it an important option for the treatment of these chronic intestinal diseases.
With the successful application of militizumab around the world, more and more doctors and patients are paying attention to its prospects in the Chinese market. However, as of now, the original drug of this drug has not been approved for marketing in China, so the specific pricing is still unclear. This situation makes patients face certain difficulties in obtaining the drug, especially when treatment is urgently needed, and patients often hope to obtain effective drugs as soon as possible.
In overseas markets, the common specifications of Milizumab are 300mg/15mL per tube, and the price of each box is usually more than 10,000 yuan. This price level is affected by many factors, including production costs, R&D investment, market demand, and medical policies in different countries. In addition, exchange rate fluctuations may also cause price changes. Therefore, it is impossible to give an exact price prediction before the selling price in the Chinese market is determined.
It is worth noting that due to the relatively short time that Militizumab has been available overseas, no generic drugs have yet entered the market. In this case, the price of the original drug is likely to remain at a high level, especially against the backdrop of strong market demand. When choosing a treatment plan, patients need to comprehensively consider factors such as the effectiveness, safety and economic burden of the drug. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.
Reference materials:https://omvoh.lilly.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)